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The cellular interactions underlying the inflammatory
component of MS are complex and involve counteracting
pro-inflammatory and regulatory lymphocyte populations.
Our understanding of these has been influenced by the
use of increasingly sophisticated versions of experimental
autoimmune encephalomyelitis (EAE) in the mouse. CD4
+ T cells are the key drivers of EAE, although the exact
means by which they exert their pathogenic influence are
still not fully understood. These are balanced by the regu-
latory activities of T cell and non-T cell populations, both
at the early stages of T cell activation in the lymphoid sys-
tem and within the CNS itself once inflammation is
underway.
To better understand the regulation of CNS inflamma-
tion we have focused on some key molecules involved in
promoting EAE pathogenesis (e.g., IL-6, GM-CSF, T-bet)
and others involved in resolution (e.g., IL-10, IFN-g).
B cells are an important source of IL-10, limiting the
size of the encephalitogenic cohort that develops. This
effect seems restricted to the lymphoid system. The key
IL-10-producing population within the CNS itself are
Foxp3+ T regulatory (Treg) cells. Mice that lack either of
these IL-10-producing populations fail to recover from
EAE.
IL-6 is required to drive pathogenic function in T cells.
Although B cells can also provide IL-6, this function is not
required. Instead, dendritic cells provide a sufficient and
short-lived source, early after T cell activation. T cells later
lose IL-6 receptor expression such that those in CNS
(both effector and Treg populations) are insensitive to
IL-6. This predicts that IL-6-blocking strategies might not
influence T cell autoaggression during ongoing disease,
but also explains why CNS Treg resist conversion to IL-
17-producing effector function. Gene expression studies
highlight marked differences between the spleen and CNS
in both the T effector and the Treg populations, providing
possible mechanistic insights into Treg function and new
therapeutic opportunities.
As part of this, the ability of CNS Treg to modulate
their expression of cytokine receptors, and therefore their
sensitivity to cytokines that might divert them from their
regulatory duties, seems a key feature in maintaining
Treg function in the face of tissue inflammation.
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